株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

持続式血糖モニタリング装置:医療機器のパイプライン評価

Continuous Glucose Monitoring Systems - Medical Devices Pipeline Assessment, 2018

発行 GlobalData 商品コード 408771
出版日 ページ情報 英文 313 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.43円で換算しております。
Back to Top
持続式血糖モニタリング装置:医療機器のパイプライン評価 Continuous Glucose Monitoring Systems - Medical Devices Pipeline Assessment, 2018
出版日: 2018年05月01日 ページ情報: 英文 313 Pages
概要

当レポートでは、世界の持続式血糖モニタリング装置 (CGM:持続血糖測定器) 市場における、主要なパイプライン製品 (医療機器) とその治験の進行状況について調査すると共に、製品特性の比較分析 (治験の進行段階別) や、主要企業のプロファイルおよび代表的製品、昨今の市場動静 (資本取引・事業提携など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • 持続式血糖モニタリング装置の概要

第3章 現在治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:領域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別
  • 現在進行中の治験

第4章 持続式血糖モニタリング装置:各企業で現在治験中のパイプライン製品

  • 持続式血糖モニタリング装置の企業:治験段階別のパイプライン製品
  • 持続式血糖モニタリング装置:治験段階別のパイプライン製品

第5章 持続式血糖モニタリング装置の企業・製品の概要

  • A. Menarini Diagnostics S.r.l.
  • Abbott Diabetes Care, Inc.
  • Advanced Biosensors-Ohio, Llc
  • Advanced Medical Electronics Corporation
  • Alcon Inc
  • Arkal Medical, Inc.
  • Azurite Technologies, Inc.
  • Bar-Ilan University
  • Bellco Srl
  • Bio-Impedance General Ltd.
  • Biorasis, Inc.
  • BioTex Inc
  • Biovotion AG
  • Brigham and Women's Hospital
  • CALISTO MEDICAL, INC. (Inactive)
  • Cardiff University
  • CGM3 Ltd
  • ConvaTec Healthcare B Sarl
  • Cyber Medical Ltd.
  • Debiotech SA
  • DexCom Inc
  • DirectSens GmbH
  • Eccrine Systems Inc
  • Echo Therapeutics Inc
  • Ecole Polytechnique Federale de Lausanne
  • eLutions Integrated Systems, Inc.
  • EyeSense GmbH
  • Flowsion A/S
  • Globe Medical Tech Inc
  • GlucoLight Corporation
  • Glucometrics, Inc.
  • Glucometrix AG
  • Glucosense Diagnostics Ltd
  • GlucoSet AS
  • Glucovation Inc
  • GluMetrics Inc
  • Glusense Ltd
  • GlySens Inc
  • GlySure Ltd
  • G-Sense Ltd.
  • Guided Therapeutics Inc
  • Hypo-Safe A/S
  • iGlyko, Inc. Company Overview 106
  • Institute of Biomedical Engineering (ISIB-CNR) (Inactive)
  • Insulet Corp
  • Integrity Applications Ltd
  • Invivomon Inc.
  • Invivosense ASA
  • iSense Corporation (Inactive)
  • Luminous Medical Inc
  • Massachusetts Institute of Technology
  • MASTInc
  • Medella Health Inc.
  • Medical Wireless Sensing Ltd
  • Medtronic plc
  • Mellitor Ltd.
  • Microchips Biotech Inc
  • mobiLIFE
  • Nemaura Medical Inc
  • Northwestern University
  • NovioSense B.V.
  • Optiscan Biomedical Corp
  • Pignolo SpA
  • PositiveID Corp
  • Prediktor AS
  • Profusa, Inc.
  • Roche Diagnostics International Ltd
  • San Meditech (Huzhou) Co., Ltd.
  • Senseonics, Incorporated
  • SensiVida Medical Technologies, Inc. (Inactive)
  • Senzime AB
  • Singapore Biomicro Pte
  • Stanford University
  • Tenax Therapeutics Inc
  • テルモ
  • The Charles Stark Draper Laboratory Inc
  • Ultradian Diagnostics LLC
  • University of Bari Aldo Moro
  • University of Bath
  • University of California Berkeley
  • University of California San Diego
  • University of South Florida
  • University of Strathclyde
  • University of Texas at Arlington
  • Vytrace, Inc.
  • Zyvex Corporation

第6章 持続式血糖モニタリング装置市場:昨今の動向

第7章 付録

図表一覧

目次
Product Code: GDME0544EPD

GlobalData's Medical Devices sector report, "Continuous Glucose Monitoring Systems - Medical Devices Pipeline Assessment, 2018" provides an overview of Continuous Glucose Monitoring Systems currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Continuous Glucose Monitoring Systems pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Continuous Glucose Monitoring Systems under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Continuous Glucose Monitoring Systems and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Continuous Glucose Monitoring Systems under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 8
  • 1.2 List of Figures 14

2 Introduction 15

  • 2.1 Continuous Glucose Monitoring Systems Overview 15

3 Products under Development 16

  • 3.1 Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development 16
  • 3.2 Continuous Glucose Monitoring Systems - Pipeline Products by Territory 17
  • 3.3 Continuous Glucose Monitoring Systems - Pipeline Products by Regulatory Path 18
  • 3.4 Continuous Glucose Monitoring Systems - Pipeline Products by Estimated Approval Date 19
  • 3.5 Continuous Glucose Monitoring Systems - Ongoing Clinical Trials 20

4 Continuous Glucose Monitoring Systems - Pipeline Products under Development by Companies 21

  • 4.1 Continuous Glucose Monitoring Systems Companies - Pipeline Products by Stage of Development 21
  • 4.2 Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development 24

5 Continuous Glucose Monitoring Systems Companies and Product Overview 27

  • 5.1 A. Menarini Diagnostics Srl Company Overview 27
  • 5.2 Abbott Diabetes Care Inc Company Overview 28
  • 5.3 Advanced Biosensors-Ohio LLC Company Overview 35
  • 5.4 Advanced Medical Electronics Corp Company Overview 36
  • 5.5 Arkal Medical, Inc. (Inactive) Company Overview 37
  • 5.6 Azurite Technologies, Inc. (Inactive) Company Overview 38
  • 5.7 Biorasis Inc Company Overview 39
  • 5.8 Biovotion AG Company Overview 40
  • 5.9 Brigham and Women's Hospital Company Overview 41
  • 5.10 CALISTO MEDICAL, INC. (Inactive) Company Overview 42
  • 5.11 CGM3 Ltd Company Overview 43
  • 5.12 City, University of London Company Overview 44
  • 5.13 Columbia University Company Overview 45
  • 5.14 ConvaTec Group Plc Company Overview 46
  • 5.15 Cyber Medical Ltd Company Overview 47
  • 5.16 Debiotech SA Company Overview 48
  • 5.17 DexCom Inc Company Overview 49
  • 5.18 DirectSens GmbH Company Overview 54
  • 5.19 Echo Therapeutics Inc Company Overview 55
  • 5.20 Ecole Polytechnique Federale de Lausanne Company Overview 58
  • 5.21 eLutions Integrated Systems, Inc. Company Overview 59
  • 5.22 EyeSense GmbH Company Overview 60
  • 5.23 Flowsion A/S Company Overview 63
  • 5.24 Gili Medical Ltd Company Overview 64
  • 5.25 Globe Medical Tech Inc Company Overview 65
  • 5.26 GlucoLight Corporation (Inactive) Company Overview 66
  • 5.27 Glucometrix AG Company Overview 67
  • 5.28 Glucosense Diagnostics Ltd (Inactive) Company Overview 68
  • 5.29 GlucoSet AS Company Overview 69
  • 5.30 Glucovation Inc Company Overview 70
  • 5.31 GluMetrics Inc Company Overview 71
  • 5.32 Glusense Ltd Company Overview 72
  • 5.33 GlySens Inc Company Overview 73
  • 5.34 GlySure Ltd Company Overview 77
  • 5.35 G-Sense Ltd. Company Overview 78
  • 5.36 iGlyko, Inc. (Inactive) Company Overview 79
  • 5.37 Indigo Diabetes NV Company Overview 80
  • 5.38 Innovosens AB Company Overview 81
  • 5.39 Institute of Biomedical Engineering (ISIB-CNR) (Inactive) Company Overview 82
  • 5.40 Insulet Corp Company Overview 83
  • 5.41 Integrated Medical Group of Irvine Company Overview 84
  • 5.42 Integrity Applications Ltd Company Overview 85
  • 5.43 Invivosense ASA (Inactive) Company Overview 87
  • 5.44 iSense Corporation (Inactive) Company Overview 88
  • 5.45 LEMM Technologies, LLC Company Overview 89
  • 5.46 Massachusetts Institute of Technology Company Overview 90
  • 5.47 Medical Wireless Sensing Ltd Company Overview 92
  • 5.48 Medtronic plc Company Overview 93
  • 5.49 Mellitor Ltd Company Overview 106
  • 5.50 Metronom Health Inc Company Overview 107
  • 5.51 Microchips Biotech Inc Company Overview 110
  • 5.52 mobiLIFE Company Overview 111
  • 5.53 Nemaura Medical Inc Company Overview 112
  • 5.54 Newton Photonics Inc Company Overview 114
  • 5.55 Northwestern University Company Overview 115
  • 5.56 Orsus Medical Ltd Company Overview 116
  • 5.57 PositiveID Corp Company Overview 117
  • 5.58 Prediktor Medical AS Company Overview 119
  • 5.59 Profusa, Inc. Company Overview 120
  • 5.60 San Meditech (Huzhou) Co., Ltd. Company Overview 121
  • 5.61 Senseonics Holdings, Inc. Company Overview 122
  • 5.62 SensiVida Medical Technologies, Inc. (Inactive) Company Overview 126
  • 5.63 Senzime AB Company Overview 127
  • 5.64 Singapore Biomicro Pte Ltd Company Overview 129
  • 5.65 Stony Brook University Company Overview 130
  • 5.66 Tenax Therapeutics Inc Company Overview 131
  • 5.67 Terumo Corp Company Overview 132
  • 5.68 Texas A&M University Company Overview 134
  • 5.69 Ultradian Diagnostics LLC Company Overview 135
  • 5.70 University of Bath Company Overview 136
  • 5.71 University of California Berkeley Company Overview 137
  • 5.72 University of California Irvine Company Overview 138
  • 5.73 University of California San Diego Company Overview 139
  • 5.74 University of South Carolina Company Overview 140
  • 5.75 University of South Florida Company Overview 141
  • 5.76 University of Technology Sydney Company Overview 142
  • 5.77 University of Texas at Arlington Company Overview 143
  • 5.78 Vytrace, Inc. Company Overview 144
  • 5.79 WaveForm Technologies Inc Company Overview 145
  • 5.80 Zyvex Corporation Company Overview 146

6 Continuous Glucose Monitoring Systems- Recent Developments 147

  • 6.1 Apr 18, 2018: Abbott Reports First-Quarter 2018 Results 147
  • 6.2 Apr 12, 2018: Henry Schein Names Christopher Pendergast To Lead Information Technology 149
  • 6.3 Apr 10, 2018: Tandem Diabetes Care Announces Preliminary First Quarter 2018 Results 150
  • 6.4 Apr 10, 2018: Alpha Omega-Henry Schein Cares Holocaust Survivors Oral Health Program Receives 2018 William J. Gees Award 150
  • 6.5 Apr 09, 2018: Henry Schein Names Mark Hillebrandt Vice President, Marketing, North America Dental Group 151
  • 6.6 Apr 09, 2018: Nemaura Medical Appoints Bashir Timol Chief Business Officer 152
  • 6.7 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics 152
  • 6.8 Apr 03, 2018: PositiveID Reports 2017 Results; Fourth Quarter Revenues Increase 47% Year Over Year 153
  • 6.9 Mar 29, 2018: Senseonics Announces Favorable Outcome of FDA Advisory Committee on the Eversense System 154
  • 6.10 Mar 28, 2018: Nemaura Medical Appoints The Ruth Group as Investor and Public Relations Counsel 155
  • 6.11 Mar 27, 2018: FDA Authorizes Marketing of the New Dexcom G6 CGM Eliminating Need for Fingerstick Blood Testing for People with Diabetes 155
  • 6.12 Mar 22, 2018: Lee's Pharmaceutical Holdings: Announcement of Annual Results for the Year Ended 31 December 2017 156
  • 6.13 Mar 14, 2018: Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement 161
  • 6.14 Mar 12, 2018: Medtronic Receives FDA Approval for Guardian Connect Continuous Glucose Monitoring (CGM) System for People Living with Diabetes 162
  • 6.15 Mar 08, 2018: WaveForm Technologies Receives Favorable Decision on Critical Glucose Monitoring Patents 162
  • 6.16 Mar 01, 2018: Nemaura Announces Expansion of Manufacturing Capabilities for SugarBEAT Commercial Launch 163
  • 6.17 Mar 01, 2018: Senseonics Announces Date for FDA Advisory Panel 164
  • 6.18 Mar 01, 2018: Tandem Diabetes Care Announces 2017 Financial Results 164
  • 6.19 Mar 01, 2018: Senseonics Announces Date for FDA Advisory Panel 166
  • 6.20 Mar 01, 2018: Callitas Health Has Big Plans For Broad Product Portfolio 166
  • 6.21 Feb 21, 2018: Insulet Reports Fourth Quarter Revenue of $130.5 Million In Fourth Quarter Of 2017 167
  • 6.22 Feb 20, 2018: Eversense CGM System, World's Longest Lasting CGM Sensor, Announces Approval and Launch of Remote Monitoring Feature for EMEA Markets 169
  • 6.23 Feb 20, 2018: New Study Demonstrates that DexCom CGM Significantly Reduces Hypoglycaemia in People with Type 1 Diabetes on MDI 169
  • 6.24 Feb 20, 2018: New study shows that DexCom CGM significantly reduces hypoglycaemia in people with type 1 diabetes with multiple daily insulin injections (MDI) 170
  • 6.25 Feb 20, 2018: Henry Schein Reports Record Fourth Quarter and Full Year 2017 Financial Results 171
  • 6.26 Feb 19, 2018: Henry Schein And Its Dental Laboratory Business, Zahn Dental, To Showcase The Company's Latest Digital Solutions At Chicago Midwinter Dental Meeting And LMT Lab Day 174
  • 6.27 Feb 16, 2018: Senzime's Year-end Bulletin 2017 175
  • 6.28 Feb 15, 2018: ProAxsis reaches the commercialization stage of its technology by reporting its first NEATstik sale 175
  • 6.29 Feb 15, 2018: ConvaTec Group Annual Results 2017 176
  • 6.30 Feb 15, 2018: ConvaTec Group Reports Annual Financial Results For 2017 177
  • 6.31 Feb 14, 2018: Ericsson, Sony Mobile and Altair Announce LTE-M eHealth Concept Demo 183
  • 6.32 Feb 13, 2018: Henry Schein Denies FTC Anti-Trust Allegations 184
  • 6.33 Feb 12, 2018: Henry Schein Named one of the 2018 World's Most Ethical Companies by The Ethisphere Institute for the Seventh Time 184
  • 6.34 Feb 09, 2018: Nemaura Medical Reports Third Quarter 2017 Financial Results 185
  • 6.35 Feb 08, 2018: Terumo Revises the Full-Year Results Forecast for FY 2017 186
  • 6.36 Feb 01, 2018: Edwards Lifesciences Reports Fourth Quarter Results 186
  • 6.37 Jan 31, 2018: Nemaura Announces Positive Results for its SugarBEAT European Clinical Program 188
  • 6.38 Jan 30, 2018: Breakthrough Study Shows that Dexcom G5 Mobile CGM Outperforms Abbott FreeStyle Libre FGM in Reducing Hypoglycaemia 188
  • 6.39 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region 190
  • 6.40 Jan 25, 2018: Terumo Announces Change of Directors and Executive Officers 190
  • 6.41 Jan 24, 2018: Abbott Reports Fourth-Quarter 2017 Results 192
  • 6.42 Jan 19, 2018: School of Engineering awarded two ERC Consolidator Grants 195
  • 6.43 Jan 17, 2018: PositiveID's E-N-G Mobile Systems 2017 Bookings Increase 100% Year Over Year 196
  • 6.44 Jan 10, 2018: UnitedHealthcare and Dexcom Bring Wearable Technology Solution, One-on-One Coaching to People Battling Type 2 Diabetes 197
  • 6.45 Jan 10, 2018: PositiveID Announces 2017 Highlights and Projects Continued 30% Growth 198
  • 6.46 Jan 09, 2018: Tandem Diabetes Care Announces Preliminary 2017 Results and Provides 2018 Guidance 199
  • 6.47 Jan 04, 2018: Abbott's Revolutionary Continuous Glucose Monitoring System, FreeStyle Libre, Now Available To Medicare Patients 200
  • 6.48 Jan 03, 2018: Callitas Announces New Interim CEO 201

7 Appendix 308

  • 7.1 Methodology 308
  • 7.2 About GlobalData 311
  • 7.3 Contact Us 311
  • 7.4 Disclaimer 311

List of Tables

1.1 List of Tables

  • Table 1: Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development 18
  • Table 2: Continuous Glucose Monitoring Systems - Pipeline Products by Territory 19
  • Table 3: Continuous Glucose Monitoring Systems - Pipeline Products by Regulatory Path 20
  • Table 4: Continuous Glucose Monitoring Systems - Pipeline Products by Estimated Approval Date 21
  • Table 5: Continuous Glucose Monitoring Systems - Ongoing Clinical Trials 22
  • Table 6: Continuous Glucose Monitoring Systems Companies - Pipeline Products by Stage of Development 23
  • Table 7: Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development 26
  • Table 8: A. Menarini Diagnostics Srl Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 9: GlucoMen Day - Product Status 29
  • Table 10: GlucoMen Day - Product Description 29
  • Table 11: Abbott Diabetes Care Inc Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 12: FreeStyle Libre Flash Glucose Monitoring System - Children - Product Status 30
  • Table 13: FreeStyle Libre Flash Glucose Monitoring System - Children - Product Description 30
  • Table 14: FreeStyle Libre Glucose Monitoring System - Consumer Version - Product Status 31
  • Table 15: FreeStyle Libre Glucose Monitoring System - Consumer Version - Product Description 31
  • Table 16: Abbott Diabetes Care Inc - Ongoing Clinical Trials Overview 32
  • Table 17: FreeStyle Libre Flash Glucose Monitoring System - Children - A Comparative Study on the Accuracy, Ease of Use and Skin Reactions Between the Enlite Sensor With Guardian 2 Link Transmitter and the FreeStyle Libre Flash Glucose Sensor 33
  • Table 18: FreeStyle Libre Flash Glucose Monitoring System - Children - An Evaluation of the Usability, Skin Reactions and Accuracy of the FreeStyle Libre Flash Glucose Monitoring System 33
  • Table 19: FreeStyle Libre Flash Glucose Monitoring System - Children - Effectiveness and Safety Study of the FreeStyle Libre Flash Glucose Monitoring System in Pediatric Populations 33
  • Table 20: FreeStyle Libre Flash Glucose Monitoring System - Children - Evaluation of Two Different Glucose Monitoring Treatments and Their Impact on Time in Target, Sleep and Quality of Life in Children with Type 1 Diabetes and Primary Caregivers 34
  • Table 21: FreeStyle Libre Flash Glucose Monitoring System - Children - FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients 34
  • Table 22: FreeStyle Libre Flash Glucose Monitoring System - Children - Paediatric Use of the Abbott Sensor Based Glucose Monitoring System - an Accuracy Evaluation 34
  • Table 23: FreeStyle Libre Flash Glucose Monitoring System - Children - Patients Perceptions of Using the Libre System Compared with Conventional SMBG in Adolescents with Type 1 Diabetes the Libre Sat Trial 35
  • Table 24: FreeStyle Libre Glucose Monitoring System - Consumer Version - Study about the Discrepancies Between Monitoring Data of FreeStyle libre and SMBG 36
  • Table 25: Advanced Biosensors-Ohio LLC Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 26: My Medibit - Product Status 37
  • Table 27: My Medibit - Product Description 37
  • Table 28: Advanced Medical Electronics Corp Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 29: Continuous Glucose Monitor - Product Status 38
  • Table 30: Continuous Glucose Monitor - Product Description 38
  • Table 31: Arkal Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 32: GlucoPod CGM System - Product Status 39
  • Table 33: GlucoPod CGM System - Product Description 39
  • Table 34: Azurite Technologies, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 35: Blood Glucose Sensor - Product Status 40
  • Table 36: Blood Glucose Sensor - Product Description 40
  • Table 37: Biorasis Inc Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 38: Glucowizzard - Product Status 41
  • Table 39: Glucowizzard - Product Description 41
  • Table 40: Biovotion AG Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 41: VSM 3 Glucose Monitoring System - Product Status 42
  • Table 42: VSM 3 Glucose Monitoring System - Product Description 42
  • Table 43: Brigham and Women's Hospital Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 44: Fluorescence Measurement Device - Product Status 43
  • Table 45: Fluorescence Measurement Device - Product Description 43
  • Table 46: CALISTO MEDICAL, INC. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 47: Glucoband - Product Status 44
  • Table 48: Glucoband - Product Description 44
  • Table 49: CGM3 Ltd Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 50: Miniaturized Implantable Continuous Glucose Monitor - Product Status 45
  • Table 51: Miniaturized Implantable Continuous Glucose Monitor - Product Description 45
  • Table 52: City, University of London Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 53: Non-Invasive Glucose Monitor - Product Status 46
  • Table 54: Non-Invasive Glucose Monitor - Product Description 46
  • Table 55: Columbia University Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 56: Wearable Continuous Blood Glucose Monitoring Device - Product Status 47
  • Table 57: Wearable Continuous Blood Glucose Monitoring Device - Product Description 47
  • Table 58: ConvaTec Group Plc Pipeline Products & Ongoing Clinical Trials Overview 48
  • Table 59: Closed Loop Continuous Glucose Monitoring System - Product Status 48
  • Table 60: Closed Loop Continuous Glucose Monitoring System - Product Description 48
  • Table 61: Cyber Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 62: Cybersensors Continuous Glucose Sensor - Product Status 49
  • Table 63: Cybersensors Continuous Glucose Sensor - Product Description 49
  • Table 64: Debiotech SA Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 65: Integrated iSense CGM And JewelPUMP - Product Status 50
  • Table 66: Integrated iSense CGM And JewelPUMP - Product Description 50
  • Table 67: DexCom Inc Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 68: DexCom CGM With Accu-Chek Insulin Delivery System - Product Status 51
  • Table 69: DexCom CGM With Accu-Chek Insulin Delivery System - Product Description 51
  • Table 70: Dexcom G5x - Product Status 52
  • Table 71: Dexcom G5x - Product Description 52
  • Table 72: G6 Continuous Glucose Monitor - Product Status 52
  • Table 73: G6 Continuous Glucose Monitor - Product Description 52
  • Table 74: DexCom Inc - Ongoing Clinical Trials Overview 53
  • Table 75: DexCom CGM With Accu-Chek Insulin Delivery System - Closed-loop Glucagon Pump for Treatment of Post-bariatric Hypoglycemia 54
  • Table 76: DexCom CGM With Accu-Chek Insulin Delivery System - Wireless Innovation for Seniors with Diabetes Mellitus: WISDM 54
  • Table 77: Dexcom G5x - Closed-loop Glucagon Pump for Treatment of Post-bariatric Hypoglycemia 55
  • Table 78: DirectSens GmbH Pipeline Products & Ongoing Clinical Trials Overview 56
  • Table 79: Continuous Blood Glucose Monitoring System - Product Status 56
  • Table 80: Continuous Blood Glucose Monitoring System - Product Description 56
  • Table 81: Echo Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 82: Gen 2 Symphony CGM System - Product Status 57
  • Table 83: Gen 2 Symphony CGM System - Product Description 57
  • Table 84: NextGen System - Product Status 58
  • Table 85: NextGen System - Product Description 58
  • Table 86: Symphony tCGM System - Home - Product Status 58
  • Table 87: Symphony tCGM System - Home - Product Description 59
  • Table 88: Symphony tCGM System - Hospital Critical Care - Product Status 59
  • Table 89: Symphony tCGM System - Hospital Critical Care - Product Description 59
  • Table 90: Ecole Polytechnique Federale de Lausanne Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 91: Viscosimetric Glucose Sensor - Product Status 60
  • Table 92: Viscosimetric Glucose Sensor - Product Description 60
  • Table 93: eLutions Integrated Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 61
  • Table 94: Optically-Efficient Miniaturized Raman Optical System - Product Status 61
  • Table 95: Optically-Efficient Miniaturized Raman Optical System - Product Description 61
  • Table 96: EyeSense GmbH Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 97: FiberSense System - Product Status 62
  • Table 98: FiberSense System - Product Description 62
  • Table 99: EyeSense GmbH - Ongoing Clinical Trials Overview 63
  • Table 100: FiberSense System - Effectiveness and Safety Study of the Percutaneous Optical Fibre Glucose Sensor (FiberSense) for Home Use in Diabetic and Prediabetic Individuals 64
  • Table 101: Flowsion A/S Pipeline Products & Ongoing Clinical Trials Overview 65
  • Table 102: Diramo System - Product Status 65
  • Table 103: Diramo System - Product Description 65
  • Table 104: Gili Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 66
  • Table 105: Diawatch - Product Status 66
  • Table 106: Diawatch - Product Description 66
  • Table 107: Globe Medical Tech Inc Pipeline Products & Ongoing Clinical Trials Overview 67
  • Table 108: Continuous Glucose Monitoring Device - Product Status 67
  • Table 109: Continuous Glucose Monitoring Device - Product Description 67
  • Table 110: GlucoLight Corporation (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 68
  • Table 111: SENTRIS-100 - Product Status 68
  • Table 112: SENTRIS-100 - Product Description 68
  • Table 113: Glucometrix AG Pipeline Products & Ongoing Clinical Trials Overview 69
  • Table 114: Non-Invasive Blood Glucose Monitoring Device - Product Status 69
  • Table 115: Non-Invasive Blood Glucose Monitoring Device - Product Description 69
  • Table 116: Glucosense Diagnostics Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 70
  • Table 117: Non-Invasive Blood Glucose Monitor - Product Status 70
  • Table 118: Non-Invasive Blood Glucose Monitor - Product Description 70
  • Table 119: GlucoSet AS Pipeline Products & Ongoing Clinical Trials Overview 71
  • Table 120: GlucoSet Sensor - Product Status 71
  • Table 121: GlucoSet Sensor - Product Description 71
  • Table 122: Glucovation Inc Pipeline Products & Ongoing Clinical Trials Overview 72
  • Table 123: SugarSenz Continuous Glucose Monitor - Product Status 72
  • Table 124: SugarSenz Continuous Glucose Monitor - Product Description 72
  • Table 125: GluMetrics Inc Pipeline Products & Ongoing Clinical Trials Overview 73
  • Table 126: GluCath Intravascular Continuous Glucose Monitor - Product Status 73
  • Table 127: GluCath Intravascular Continuous Glucose Monitor - Product Description 73
  • Table 128: Glusense Ltd Pipeline Products & Ongoing Clinical Trials Overview 74
  • Table 129: Glyde CGM - Product Status 74
  • Table 130: Glyde CGM - Product Description 74
  • Table 131: GlySens Inc Pipeline Products & Ongoing Clinical Trials Overview 75
  • Table 132: Eclipse ICGM System - Product Status 75
  • Table 133: Eclipse ICGM System - Product Description 75
  • Table 134: Second Generation ICGM System - Product Status 76
  • Table 135: Second Generation ICGM System - Product Description 76
  • Table 136: GlySens Inc - Ongoing Clinical Trials Overview 77
  • Table 137: Eclipse ICGM System - Accuracy of Long-term Implantable Glucose Monitoring in Type 1 Diabetes 78
  • Table 138: Eclipse ICGM System - Function of Implanted Glucose Sensor 2 78
  • Table 139: GlySure Ltd Pipeline Products & Ongoing Clinical Trials Overview 79
  • Table 140: GlySure System - Product Status 79
  • Table 141: GlySure System - Product Description 79
  • Table 142: G-Sense Ltd. Pipeline Products & Ongoing Clinical Trials Overview 80
  • Table 143: G-Sense Device - Product Status 80
  • Table 144: G-Sense Device - Product Description 80
  • Table 145: iGlyko, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 81
  • Table 146: iGlyko System - Product Status 81
  • Table 147: iGlyko System - Product Description 81
  • Table 148: Indigo Diabetes NV Pipeline Products & Ongoing Clinical Trials Overview 82
  • Table 149: Needle-Free Glucose Sensor - Product Status 82
  • Table 150: Needle-Free Glucose Sensor - Product Description 82
  • Table 151: Innovosens AB Pipeline Products & Ongoing Clinical Trials Overview 83
  • Table 152: Diabsens - Product Status 83
  • Table 153: Diabsens - Product Description 83

List of Figures

1.2 List of Figures

  • Figure 1: Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development 18
  • Figure 2: Continuous Glucose Monitoring Systems - Pipeline Products by Territory 19
  • Figure 3: Continuous Glucose Monitoring Systems - Pipeline Products by Regulatory Path 20
  • Figure 4: Continuous Glucose Monitoring Systems - Pipeline Products by Estimated Approval Date 21
  • Figure 5: Continuous Glucose Monitoring Systems - Ongoing Clinical Trials 22
Back to Top